Table 2 Cancer and chemotherapy characteristics.
All patients | Group of capping | P-value | |||||
|---|---|---|---|---|---|---|---|
[0–10[ | [10–50[ | [50–90[ | [90–100] | ||||
No. of patients (%) | 130 (100%) | 13 (10%) | 42 (32.3%) | 50 (38.5%) | 25 (19.2%) | ||
Type of cancer | Infiltrating duct carcinoma | 104 (80%) | 10 (76.9%) | 32 (76.2%) | 40 (80%) | 22 (88%) | 0.705 |
Infiltrating lobular carcinoma | 21 (16.2%) | 1 (7.7%) | 8 (19%) | 9 (18%) | 3 (12%) | 0.802 | |
Other carcinoma | 5 (3.8%) | 2 (15.4%) | 2 (4.8%) | 1 (2%) | 0 (0%) | 0.853 | |
Grade SBR | 1 | 6 (4.6%) | 1 (7.7%) | 2 (4.8%) | 2 (4%) | 1 (4%) | 0.79 |
2 | 67 (51.5%) | 5 (38.5%) | 21 (50%) | 25 (50%) | 16 (64%) | ||
3 | 55 (42.3%) | 7 (53.8%) | 18 (42.9%) | 22 (44%) | 8 (32%) | ||
MD | 2 (1.5%) | 0 (0%) | 1 (2.4%) | 1 (2%) | 0 (0%) | ||
Metastasis status (M) | MX | 16 (12.3%) | 2 (15.4%) | 5 (11.9%) | 7 (14%) | 2 (8%) | – |
M0 | 114 (87.6%) | 11 (84.6%) | 37 (88%) | 43 (86%) | 23 (92%) | ||
HER2 status | Positive | 23 (17.7%) | 3 (23.1%) | 10 (23.8%) | 7 (14%) | 3 (12%) | 0.472 |
Negative | 107 (82.3%) | 10 (76.9%) | 32 (76.2%) | 43 (86%) | 22 (88%) | ||
Estrogen receptors | Positive | 96 (73.8%) | 9 (69.2%) | 27 (64.3%) | 39 (78%) | 21 (84%) | 0.26 |
Negative | 34 (26.2%) | 4 (30.8%) | 15 (35.7%) | 11 (22%) | 4 (16%) | ||
Progesterone receptors | Positive | 79 (60.8%) | 10 (76.9%) | 19 (45.2%) | 30 (60%) | 20 (80%) | 0.023* |
Negative | 51 (39.2%) | 3 (23.1%) | 23 (54.8%) | 20 (40%) | 5 (20%) | ||
Chemotherapy | Adjuvant | 113 (86.9%) | 13 (100%) | 31 (73.8%) | 46 (92%) | 23 (92%) | 0.028* |
Neoadjuvant | 17 (13.1%) | 0 (0%) | 11 (26.2%) | 4 (8%) | 2 (8%) | ||
Number of cycle received, mean [± SD] | 7(± 3.4) | 6.5 (± 3.5) | 8 (± 4) | 6.5 (± 2.9) | 6 (± 2.8) | 0.034* | |
